147 related articles for article (PubMed ID: 37940790)
21. Design and synthesis of polyhydroxy steroids as selective inhibitors against AKR1B10 and molecular docking.
Chen W; Chen X; Zhou S; Zhang H; Wang L; Xu J; Hu X; Yin W; Yan G; Zhang J
Steroids; 2016 Jun; 110():1-8. PubMed ID: 26968129
[TBL] [Abstract][Full Text] [Related]
22. Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.
Ebert B; Kisiela M; Wsól V; Maser E
Chem Biol Interact; 2011 May; 191(1-3):239-49. PubMed ID: 21215737
[TBL] [Abstract][Full Text] [Related]
23. Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.
Takemura M; Endo S; Matsunaga T; Soda M; Zhao HT; El-Kabbani O; Tajima K; Iinuma M; Hara A
J Nat Prod; 2011 May; 74(5):1201-6. PubMed ID: 21561086
[TBL] [Abstract][Full Text] [Related]
24. Investigation of the Potential of Bile Acid Methyl Esters as Inhibitors of Aldo-keto Reductase 1C2: Insight from Molecular Docking, Virtual Screening, Experimental Assays and Molecular Dynamics.
Marinović MA; Petri ET; Grbović LM; Vasiljević BR; Jovanović-Šanta SS; Bekić SS; Ćelić AS
Mol Inform; 2022 Oct; 41(10):e2100256. PubMed ID: 35393780
[TBL] [Abstract][Full Text] [Related]
25. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target effect for the Bcr-Abl tyrosine kinase inhibitor dasatinib.
Büküm N; Novotná E; Morell A; Želazková J; Laštovičková L; Čermáková L; Portillo R; Solich P; Wsól V
Biochem Pharmacol; 2021 Oct; 192():114710. PubMed ID: 34339712
[TBL] [Abstract][Full Text] [Related]
27. Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members.
O'connor T; Ireland LS; Harrison DJ; Hayes JD
Biochem J; 1999 Oct; 343 Pt 2(Pt 2):487-504. PubMed ID: 10510318
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of human aldose reductase-like protein (AKR1B10) by α- and γ-mangostins, major components of pericarps of mangosteen.
Soda M; Endo S; Matsunaga T; Zhao HT; El-Kabbani O; Iinuma M; Yamamura K; Hara A
Biol Pharm Bull; 2012; 35(11):2075-80. PubMed ID: 23123477
[TBL] [Abstract][Full Text] [Related]
29. Tolrestat acts atypically as a competitive inhibitor of the thermostable aldo-keto reductase Tm1743 from Thermotoga maritima.
Zhang C; Min Z; Liu X; Wang C; Wang Z; Shen J; Tang W; Zhang X; Liu D; Xu X
FEBS Lett; 2020 Feb; 594(3):564-580. PubMed ID: 31573681
[TBL] [Abstract][Full Text] [Related]
30. Human and rodent aldo-keto reductases from the AKR1B subfamily and their specificity with retinaldehyde.
Ruiz FX; Moro A; Gallego O; Ardèvol A; Rovira C; Petrash JM; Parés X; Farrés J
Chem Biol Interact; 2011 May; 191(1-3):199-205. PubMed ID: 21329680
[TBL] [Abstract][Full Text] [Related]
31. Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids.
Endo S; Matsunaga T; Mamiya H; Ohta C; Soda M; Kitade Y; Tajima K; Zhao HT; El-Kabbani O; Hara A
Arch Biochem Biophys; 2009 Jul; 487(1):1-9. PubMed ID: 19464995
[TBL] [Abstract][Full Text] [Related]
32. The hop-derived compounds xanthohumol, isoxanthohumol and 8-prenylnaringenin are tight-binding inhibitors of human aldo-keto reductases 1B1 and 1B10.
Seliger JM; Misuri L; Maser E; Hintzpeter J
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):607-614. PubMed ID: 29532688
[TBL] [Abstract][Full Text] [Related]
33. Novel chemical scaffolds of the tumor marker AKR1B10 inhibitors discovered by 3D QSAR pharmacophore modeling.
Kumar R; Son M; Bavi R; Lee Y; Park C; Arulalapperumal V; Cao GP; Kim HH; Suh JK; Kim YS; Kwon YJ; Lee KW
Acta Pharmacol Sin; 2015 Aug; 36(8):998-1012. PubMed ID: 26051108
[TBL] [Abstract][Full Text] [Related]
34. Glycyrrhetinic acid attenuates disturbed vitamin a metabolism in non-alcoholic fatty liver disease through AKR1B10.
Shi L; Guo S; Zhang S; Gao X; Liu A; Wang Q; Zhang T; Zhang Y; Wen A
Eur J Pharmacol; 2020 Sep; 883():173167. PubMed ID: 32485245
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of aldo-keto reductase family 1 member B10 by unsaturated fatty acids.
Hara A; Endo S; Matsunaga T; Soda M; El-Kabbani O; Yashiro K
Arch Biochem Biophys; 2016 Nov; 609():69-76. PubMed ID: 27665999
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of an aldo-keto reductase gene signature with prognostic significance in colon cancer via activation of epithelial to mesenchymal transition and the p70S6K pathway.
Demirkol Canlı S; Seza EG; Sheraj I; Gömçeli I; Turhan N; Carberry S; Prehn JHM; Güre AO; Banerjee S
Carcinogenesis; 2020 Sep; 41(9):1219-1228. PubMed ID: 32628753
[TBL] [Abstract][Full Text] [Related]
37. Bombyx mori-derived aldo-keto reductase AKR2E8 detoxifies aldehydes present in mulberry leaves.
Yamamoto K; Endo S
Chem Biol Interact; 2022 Jan; 351():109717. PubMed ID: 34737151
[TBL] [Abstract][Full Text] [Related]
38. Identification of aldo-keto reductase AKR1B10 as a selective target for modification and inhibition by prostaglandin A(1): implications for antitumoral activity.
Díez-Dacal B; Gayarre J; Gharbi S; Timms JF; Coderch C; Gago F; Pérez-Sala D
Cancer Res; 2011 Jun; 71(12):4161-71. PubMed ID: 21507934
[TBL] [Abstract][Full Text] [Related]
39. Cancer biomarker AKR1B10 and carbonyl metabolism.
Balendiran GK; Martin HJ; El-Hawari Y; Maser E
Chem Biol Interact; 2009 Mar; 178(1-3):134-7. PubMed ID: 19028477
[TBL] [Abstract][Full Text] [Related]
40. Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
Gallego O; Ruiz FX; Ardèvol A; Domínguez M; Alvarez R; de Lera AR; Rovira C; Farrés J; Fita I; Parés X
Proc Natl Acad Sci U S A; 2007 Dec; 104(52):20764-9. PubMed ID: 18087047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]